Palmitoylethanolamide (PEA): Uses, Benefits, Dosage & Safety

Last updated: August 2026 · Reviewed by the FactoWiki Editorial Team for clarity and source accuracy

What is Palmitoylethanolamide (PEA)?

Palmitoylethanolamide is an endogenous fatty acid amide, part of the same family as the endocannabinoid anandamide though it does not bind cannabinoid receptors directly. Your body makes it in cells under stress. As a supplement it is sold in micronised or ultra-micronised forms, which matter because plain PEA is poorly absorbed.

What Palmitoylethanolamide (PEA) is commonly used for

Chronic pain, neuropathic pain including sciatica and diabetic neuropathy, and inflammatory conditions. In parts of Europe it is sold as a medical food rather than an ordinary supplement.

How Palmitoylethanolamide (PEA) works

PEA activates PPAR-alpha, a nuclear receptor that downregulates inflammatory gene expression. It also appears to reduce mast cell and glial cell activation — both implicated in the persistence of chronic pain. Because it acts on the cells that maintain pain rather than blocking pain signals directly, its effect builds over weeks rather than working like an analgesic.

What the evidence says

Each claim below is tied to the specific study behind it, rather than to a general reading list.

• Meta-analysis of randomised trials found PEA reduced chronic and neuropathic pain scores versus control. Paladini et al., Pain Physician, 2016 — pooled analysis of randomised and controlled studies. (PubMed)
• PEA acts through PPAR-alpha to reduce inflammatory signalling. Lo Verme et al., Molecular Pharmacology, 2005 — mechanistic study. (PubMed)
• Systematic review found consistent safety with no serious adverse events. Gabrielsson et al., British Journal of Clinical Pharmacology, 2016 — systematic review. (PubMed)

Typical dosage used in studies

300–1,200 mg per day, most commonly 600 mg twice daily for the first two months then 600 mg daily. Micronised or ultra-micronised forms are what the trials used; ordinary PEA has much lower bioavailability, so an unspecified form is a genuine problem.

Side effects and safety

PEA has one of the cleanest safety records in this category. Trials consistently report adverse event rates indistinguishable from placebo, and no serious adverse events have been attributed to it. It is not sedating and is not addictive.

Medication interactions and who should avoid Palmitoylethanolamide (PEA)

Sources & further reading

The claim-level citations above are drawn from these sources:

• Paladini et al., Pain Physician, 2016 — pooled analysis of randomised and controlled studies — find on PubMed
• Lo Verme et al., Molecular Pharmacology, 2005 — mechanistic study — find on PubMed
• Gabrielsson et al., British Journal of Clinical Pharmacology, 2016 — systematic review — find on PubMed
• NIH Office of Dietary Supplements
• NIH National Center for Complementary and Integrative Health

Frequently asked questions

Is PEA a painkiller?

Not in the usual sense. It does not block pain signals for immediate relief. It reduces the inflammatory and glial activity that sustains chronic pain, so the effect builds over 4–8 weeks.

Does the micronised form matter?

Yes, considerably. Plain PEA is poorly absorbed. The trials used micronised or ultra-micronised preparations. A label that does not specify is a reason to look elsewhere.

Can PEA replace my neuropathic pain medication?

No. It has been studied alongside standard treatment, not instead of it. Any change to prescribed pain medication is a decision for your doctor.

General information, not medical advice.